| Literature DB >> 36034362 |
Pietro Princi1, Gaetano Gallo2, Serena Elisa Tempera1, Antonio Umbriano3, Marta Goglia4, Federica Andreoli1, Casimiro Nigro5.
Abstract
The most fearsome complication in thyroid surgery is the temporary or definitive recurrent laryngeal nerve (RLN) injury. The aim of our study was to evaluate the impact of intraoperative neuromonitoring (IONM) on postoperative outcomes after thyroid and parathyroid surgery. From October 2014 to February 2016, a total of 80 consecutive patients, with high risk of RLN injuries, underwent thyroid and parathyroid surgery. They were divided in two groups (IONM group and control group), depending on whether neuromonitoring was used or not. We used the Nerve Integrity Monitoring System (NIM)-Response 3.0® (Medtronic Xomed®). The operation time (p = 0.014). and the length of hospital stay (LOS) (p = 0.14) were shorter in the IONM group. Overall mean follow-up was 96.7 ± 14.3 months. The rate of transient RLN palsy was 2.6% in IONM group and 2.5% in the control group (p = not significant). Only one case of definitive RLN injury was reported in control group. No differences were reported between the two groups in terms of temporary or definitive RLN injury. Routine use of IOMN increases the surgery cost, but overall, it leads to long-term cost savings thanks to the reduction of both operating times (106.3 ± 38.7 vs 128.1 ± 39.3, p: 0.01) and LOS (3.2 ± 1.5 vs 3.7 ± 1.5 days, p = 0.14). Anatomical visualization of RLN remains the gold standard in thyroid and parathyroid surgery. Nevertheless, IONM is proved to be a valid help without the ambition to replace surgeon's experience.Entities:
Keywords: cost analysis; intraoperative neuromonitoring (IONM); parathyroid surgery; recurrent laryngeal nerve; thyroid surgery; thyroidectomy
Year: 2022 PMID: 36034362 PMCID: PMC9399456 DOI: 10.3389/fsurg.2022.983966
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Demographic and clinical characteristics of the included patients.
| All patients | C-group | IONM-group | ||
|---|---|---|---|---|
| Patients | 80 | 40 | 40 | – |
| Age (±SD | 50.6 ± 13.7 | 49 ± 16.5 | 51.4 ± 11.4 | NS |
| Male/Female | 21 (26.2%)/59 (73.7%) | 10 (25%)/30 (75%) | 11 (27.5%)/29 (72.5%) | NS |
| Mean follow-up time (±SD | 96.7 ± 14.3 | 83.06 ± 5.41 | 110.30 ± 1.83 | NS |
SD standard deviation.
NS, not significant.
Procedures performed.
| Surgical procedures | All patients | C-group | IONM-group |
|---|---|---|---|
| Total thyroidectomy | 58 (72.5%) | 27 (67.5%) | 31 (77.5%) |
| Completion thyroidectomy | 4 (5%) | 2 (5%) | 2 (5%) |
| Thyroid lobectomy | 2 (2.5%) | 2 (5%) | 0 |
| Parathyroidectomy | 1 (1.2%) | 1 (2.5%) | 0 |
| Total thyroidectomy + Parathyroidectomy | 1 (1.2%) | 0 | 1 (2.5%) |
| Total thyroidectomy + Central Neck lymphadenectomy | 11 (13.7%) | 6 (15%) | 5 (12.5%) |
| Total thyroidectomy + Central Neck lymphadenectomy + unilateral lateral neck lymphadenectomy | 3 (3.7%) | 2 (5%) | 1 (2.5%) |
Pathological characteristics and follow up of the included patients.
| Histology subtypes | All patients | C-group | IONM-group |
|---|---|---|---|
| 80 | 40 | 40 | |
| Struma | 37 (46.2%) | 15 (37.5%) | 22 (55%) |
| Follicular adenoma | 7 (8.7%) | 5 (12.5%) | 2 (5%) |
| Parathyroid adenoma | 1 (1.2%) | 1 (2.5%) | 0 |
| Papillary thyroid cancer | 27 (33.7%) | 14 (35%) | 13 (32.5%) |
| Papillary thyroid cancer + Lymph nodes metastases | 5 (6.2%) | 4 (10%) | 1 (2.5%) |
| Papillary thyroid cancer + Parathyroid adenoma | 1 (1.2%) | 0 | 1 (2.5%) |
| Microfollicular carcinoma | 1 (1.2%) | 1 (2.5%) | 0 |
| Poor differentiated carcinoma | 1 (1.2%) | 0 | 1 (2.5%) |
Procedural details.
| Mean operative time (±SDa) (range) min | 117.2 ± 40.3 | 106.3 ± 38.7 | 128.1 ± 39.3 | 0.014 |
| Mean hospital stay (±SDa) (range) days | 3.5 ± 1.5 | 3.2 ± 1.5 | 3.7 ± 1.5 | 0.14 |
| Transient laryngeal nerve palsy | 4 (2.5%)* | 2 (2.6%)* | 2 (2.5%)* | 0.97 |
| Definitive laryngeal nerve palsy y/n | 1 (0.6%)* | 0* | 1 (1.25%)* | 0.32 |
SD, standard deviation.
*Considering only RLN at risk.
Clinical characteristics and presentation of the patients enrolled.
| Preoperative Diagnosis | All patients | C-group | IONM-group |
|---|---|---|---|
| Multinodular goiter | 36 (45%) | 13 (32.5%) | 23 (57.5%) |
| Recurrent goiter | 4 (5%) | 2 (5%) | 2 (5%) |
| Toxic goiter | 9 (11.2%) | 3 (7.5%) | 6 (15%) |
| Primary hyperparathyroidism | 1 (1.2%) | 1 (2.5%) | 0 |
| Suspicious thyroid cancer | 17 (21.2%) | 14 (35%) | 3 (7.5%) |
| Thyroid cancer | 12 (15%) | 6 (15%) | 6 (15%) |
| Thyroid lodge abscess | 1 (1.2%) | 1 (2.5%) | 0 |